Total submissions: 3
Submitter | RCV | SCV | Clinical significance | Condition | Last evaluated | Review status | Method | Comment |
---|---|---|---|---|---|---|---|---|
Ce |
RCV001816386 | SCV002062569 | likely pathogenic | not provided | 2021-12-01 | criteria provided, single submitter | clinical testing | |
Institute of Human Genetics, |
RCV002267641 | SCV002549824 | pathogenic | Bietti crystalline corneoretinal dystrophy | 2022-06-17 | criteria provided, single submitter | clinical testing | This variant was identified as compound heterozygous with NM_207352.4:c.801+1G>A._x000D_ Criteria applied: PVS1, PM3_SUP, PP4 |
Labcorp Genetics |
RCV001816386 | SCV004426883 | likely pathogenic | not provided | 2023-04-07 | criteria provided, single submitter | clinical testing | In summary, the currently available evidence indicates that the variant is pathogenic, but additional data are needed to prove that conclusively. Therefore, this variant has been classified as Likely Pathogenic. Algorithms developed to predict the effect of sequence changes on RNA splicing suggest that this variant may disrupt the consensus splice site. ClinVar contains an entry for this variant (Variation ID: 1335569). This variant has not been reported in the literature in individuals affected with CYP4V2-related conditions. This variant is present in population databases (rs767779208, gnomAD 0.1%). This sequence change affects an acceptor splice site in intron 3 of the CYP4V2 gene. It is expected to disrupt RNA splicing. Variants that disrupt the donor or acceptor splice site typically lead to a loss of protein function (PMID: 16199547), and loss-of-function variants in CYP4V2 are known to be pathogenic (PMID: 15042513, 25118264). |